These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35438025)

  • 1. Adherence and blood pressure control in patients with primary aldosteronism.
    Nikrýnová Nguyen TMP; Štrauch B; Petrák O; Krátká Z; Holaj R; Kurcová I; Marešová V; Pilková A; Hartinger J; Waldauf P; Zelinka T; Widimský J
    Blood Press; 2022 Dec; 31(1):58-63. PubMed ID: 35438025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
    Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
    Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
    Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
    J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
    Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
    Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
    Guasti L; Gaudio G; Lupi A; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Sarzani R; Vanasia M; Maffioli P; Derosa G
    Drug Des Devel Ther; 2017; 11():2293-2300. PubMed ID: 28831241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
    Pechère-Bertschi A; Herpin D; Lefebvre H
    Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
    Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
    Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension.
    Siddiqui M; Judd EK; Dudenbostel T; Gupta P; Tomaszewski M; Patel P; Oparil S; Calhoun DA
    Hypertension; 2020 Feb; 75(2):510-515. PubMed ID: 31813346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
    Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.